Why Analysts See Tenet Healthcare (THC) as One of the Best Bargains on the NYSE Right Now
Tenet Healthcare Corporation (NYSE: THC) is increasingly being flagged by analysts as one of the more attractively priced stocks on the Big Board. On April 30, the Dallas-based hospital operator reported a robust first quarter for 2026, with net income attributable to common shareholders hitting $702 million, or $8.01 per diluted share — nearly doubling the $406 million recorded in the same period last year. Adjusted diluted earnings per share rose 10.6% to $4.82, while consolidated Adjusted EBITDA held steady at $1.162 billion, buoyed by tight expense controls and solid revenue gains across both its hospital and ambulatory care segments.
The ambulatory care division, operated through United Surgical Partners International, saw net operating revenues jump 10.6% to $1.32 billion. Segment Adjusted EBITDA increased 6.1% to $484 million, fueled by acquisitions and a 5.3% rise in same-facility system-wide net patient service revenues. The growth was attributed to a favorable shift in service mix toward higher-acuity procedures, a trend that industry observers say could persist as outpatient settings continue to absorb more complex surgeries.
Tenet also strengthened its balance sheet during the quarter, generating $1.641 billion in net cash from operations. The company used $318 million to repurchase 1.35 million shares of common stock and finalized a major contract restructuring with CommonSpirit Health — a move analysts say could unlock longer-term operational efficiencies. Management reaffirmed its full-year 2026 Adjusted EBITDA forecast in the range of $4.485 billion to $4.785 billion, underscoring confidence in both organic growth and future deal-making.
The broader healthcare services landscape has been under pressure from labor costs and reimbursement headwinds, yet Tenet’s diversified model — spanning acute-care hospitals, ambulatory surgery centers, and urgent care — has helped it weather the storm better than many peers. With a forward price-to-earnings multiple that still lags the sector average, several sell-side analysts argue the stock offers a rare combination of growth and value at current levels.
While we acknowledge THC’s potential as an investment, we believe certain AI stocks offer greater upside potential with lower downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT:33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.